Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 6,370.00
-130.00 (-2.00%)
Last updated: Sep 1, 2026, 2:31 PM KST
Prestige BioPharma Balance Sheet
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 63,428 | 115,378 | 219,433 | 125,022 | 268,651 | 458,975 |
Short-Term Investments | 2,467 | 58,334 | 3,058 | 176,390 | 25,584 | - |
Trading Asset Securities | - | - | - | - | 9,035 | 377.68 |
Cash & Short-Term Investments | 65,894 | 173,712 | 222,492 | 301,412 | 303,270 | 459,353 |
Cash Growth | -69.10% | -21.92% | -26.18% | -0.61% | -33.98% | 849.10% |
Accounts Receivable | 495.33 | 607.07 | 391.6 | 132.72 | - | - |
Receivables | 495.33 | 607.07 | 391.6 | 132.72 | - | - |
Inventory | 35,543 | 26,995 | 18,103 | 7,146 | 2,157 | - |
Prepaid Expenses | 2,960 | 1,641 | 2,733 | 2,731 | - | - |
Other Current Assets | 1,568 | 7,049 | 6,632 | 53.44 | 6,139 | 584.08 |
Total Current Assets | 106,460 | 210,004 | 250,352 | 311,476 | 311,566 | 459,937 |
Property, Plant & Equipment | 443,892 | 341,657 | 327,062 | 310,438 | 38,342 | 6,437 |
Long-Term Investments | - | - | - | - | 74,710 | 24,159 |
Goodwill | 11,749 | 10,530 | 10,785 | 10,192 | - | - |
Other Intangible Assets | 42,824 | 30,056 | 31,327 | 29,877 | 4,288 | 450.33 |
Long-Term Deferred Charges | 159,891 | 152,882 | 91,643 | 78,843 | 61,024 | 108,573 |
Other Long-Term Assets | 1,649 | 525.18 | 551.5 | 775.14 | 9,883 | 4,611 |
Total Assets | 766,465 | 745,654 | 711,720 | 741,600 | 499,813 | 604,166 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 5,479 | 5,864 | 2,282 | 462.15 | 2,624 | - |
Accrued Expenses | 2,897 | 4,872 | 5,975 | 6,150 | 4,923 | 3,552 |
Short-Term Debt | 63,341 | 95,939 | 36,954 | 31,188 | - | 2,873 |
Current Portion of Long-Term Debt | - | 14,083 | 10,891 | 31,176 | - | - |
Current Portion of Leases | 624.9 | 1,018 | 950.81 | 1,682 | 1,593 | 1,326 |
Current Unearned Revenue | - | - | - | - | - | 565 |
Other Current Liabilities | 52,791 | 43,546 | 88,805 | 64,231 | 32,654 | 5,730 |
Total Current Liabilities | 125,133 | 165,322 | 145,857 | 134,888 | 41,794 | 14,046 |
Long-Term Debt | 24,462 | 32,498 | 40,247 | 50,190 | - | - |
Long-Term Leases | 383.62 | 641.93 | 624.04 | 1,326 | 2,656 | 3,571 |
Long-Term Unearned Revenue | - | - | - | - | 25,427 | 11,588 |
Long-Term Deferred Tax Liabilities | 31,492 | 7,310 | 7,755 | 7,368 | - | - |
Other Long-Term Liabilities | 30,316 | 31,572 | 1,734 | 1,593 | 0 | - |
Total Liabilities | 211,788 | 237,343 | 196,219 | 195,365 | 69,877 | 29,206 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 795,636 | 713,096 | 730,340 | 690,175 | 679,713 | 594,072 |
Additional Paid-In Capital | -35,264 | -31,606 | 7,865 | 7,286 | 7,175 | - |
Retained Earnings | -348,384 | -266,271 | -294,797 | -246,151 | -259,601 | -27,954 |
Comprehensive Income & Other | 61,349 | -4,209 | -4,321 | -798.76 | 2,649 | 8,843 |
Total Common Equity | 473,335 | 411,010 | 439,087 | 450,511 | 429,936 | 574,961 |
Minority Interest | 81,342 | 97,301 | 76,414 | 95,724 | - | - |
Shareholders' Equity | 554,678 | 508,311 | 515,502 | 546,235 | 429,936 | 574,961 |
Total Liabilities & Equity | 766,465 | 745,654 | 711,720 | 741,600 | 499,813 | 604,166 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 88,812 | 144,179 | 89,667 | 115,561 | 4,249 | 7,771 |
Net Cash (Debt) | -22,917 | 29,533 | 132,825 | 185,851 | 299,020 | 451,582 |
Net Cash Growth | - | -77.77% | -28.53% | -37.85% | -33.78% | 892.04% |
Net Cash Per Share | -381.20 | 490.33 | 2215.00 | 3092.56 | 4975.70 | 8751.18 |
Filing Date Shares Outstanding | 60.33 | 60.19 | 300.48 | 300.48 | 300.48 | 300.48 |
Total Common Shares Outstanding | 60.33 | 60.19 | 300.48 | 300.48 | 300.48 | 300.48 |
Working Capital | -18,673 | 44,682 | 104,494 | 176,588 | 269,771 | 445,890 |
Book Value Per Share | 7845.71 | 6828.29 | 1461.28 | 1499.30 | 1430.83 | 1913.47 |
Tangible Book Value | 418,762 | 370,424 | 396,976 | 410,442 | 425,647 | 574,510 |
Tangible Book Value Per Share | 6941.14 | 6154.01 | 1321.13 | 1365.95 | 1416.55 | 1911.97 |
Land | 135,206 | 27,332 | 27,704 | 26,567 | 12,055 | - |
Buildings | 138,682 | 136,640 | 77,472 | 76,415 | - | - |
Machinery | 93,746 | 79,512 | 72,427 | 51,848 | 10,175 | 3,455 |
Construction In Progress | 90,004 | 110,263 | 152,876 | 169,147 | 15,415 | - |